News and updates

US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology

August 23, 2018

Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) – Agendia, Inc., a world leader in precision oncology, announced today that US Oncology Research, one of the nation’s largest research…

Read more

An Update on Agendia’s Precision Oncology Achievements in Breast Cancer

August 7, 2018

  As we close out the first half of 2018, I’d like to take a moment to reflect on Agendia’s recent achievements as a global leader in precision oncology and provide an update on forward-looking expansions that will have a positive impact on patients and their doctors. Our mission is to provide best in class…

Read more

Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations

July 25, 2018

IRVINE, CA and AMSTERDAM, NETHERLANDS – 25 July 2018 – Agendia, Inc., a world leader in precision oncology, today announced the completion of $35 million in financing from investment funds managed by Athyrium Capital Management LP, a leading global investor in innovative, high-growth companies across the healthcare sector. Proceeds from the financing will accelerate commercial…

Read more

An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:

June 12, 2018

One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question. The recent results from the TAILORx clinical trial evaluating Oncotype DX are important for patients and their oncologists, but they also…

Read more